ENDRA Life Sciences (NDRA) Cash & Equivalents (2016 - 2026)

ENDRA Life Sciences (NDRA) has 11 years of Cash & Equivalents data on file, last reported at $356462.0 in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $356462.0, down 82.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $356462.0 (down 82.74% YoY), and the FY2025 annual result was $762365.0, down 76.39% from the prior year.
• Cash & Equivalents slipped to $356462.0 in Q1 2026 per NDRA's latest filing, from $762365.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $11.3 million in Q2 2022 and troughed at $356462.0 in Q1 2026.
• A 5-year average of $3.9 million and a median of $3.2 million in 2024 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 81.98% in 2025 and fell as far as 83.27% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $4.9 million in 2022, then sank by 42.04% to $2.8 million in 2023, then grew by 13.96% to $3.2 million in 2024, then slumped by 76.39% to $762365.0 in 2025, then sank by 53.24% to $356462.0 in 2026.
• Business Quant data shows NDRA's Cash & Equivalents at $356462.0 in Q1 2026, $762365.0 in Q4 2025, and $794036.0 in Q3 2025.